Exploring the Benefits of Parsabiv: A New Treatment for Secondary Hyperparathyroidism

Introduction

Secondary hyperparathyroidism (SHPT) is a condition in which the parathyroid glands produce too much parathyroid hormone (PTH), resulting in high calcium levels in the blood. This can lead to a variety of health problems, including kidney stones, bone loss, and even death. Parsabiv is a new treatment for SHPT that has recently been approved by the U.S. Food and Drug Administration (FDA). This article will explore the benefits of Parsabiv and how it may be used to treat SHPT.

What is Secondary Hyperparathyroidism?

Secondary hyperparathyroidism (SHPT) is a condition in which the parathyroid glands produce too much parathyroid hormone (PTH). This can occur when the kidneys cannot remove enough calcium from the blood, leading to high calcium levels. This can cause a variety of health problems, including kidney stones, bone loss, and even death. SHPT is most commonly seen in people with chronic kidney disease (CKD).

What is Parsabiv?

Parsabiv (etelcalcetide) is a new treatment for SHPT that was approved by the U.S. Food and Drug Administration (FDA) in 2017. It is a calcimimetic, a type of drug that works by blocking the action of PTH, thus reducing calcium levels in the blood. Parsabiv is administered intravenously three times a week.

Benefits of Parsabiv

Parsabiv has been shown to be effective in reducing calcium levels in the blood and improving symptoms of SHPT. In clinical trials, it was found to reduce PTH levels by up to 50% and calcium levels by up to 20%. It was also found to reduce the risk of bone fractures and improve kidney function in patients with CKD. In addition, Parsabiv is well-tolerated and has few side effects. The most common side effects are nausea, vomiting, and dizziness. It is also convenient to use, as it is administered intravenously only three times a week.

Conclusion

Parsabiv is a new treatment for secondary hyperparathyroidism (SHPT) that has been approved by the U.S. Food and Drug Administration (FDA). It has been shown to be effective in reducing calcium levels in the blood and improving symptoms of SHPT. In addition, it is well-tolerated and has few side effects, and is convenient to use, as it is administered intravenously only three times a week. For these reasons, Parsabiv may be an effective treatment option for those with SHPT.